MBF Therapeutics Inc.

General Information

Company Name

Founded Year

2008

Location (Offices)

Founders / Decision Makers

Number of Employees

Industries

Biotechnology, Health and Wellness, Life Sciences

Funding Stage

Grant

Social Media

MBF Therapeutics Inc. - Company Profile

MBF Therapeutics Inc. is a biotechnology startup that focuses on developing next-generation immunotherapeutics for the life sciences industry. The company's innovative T-Max™ immunotherapeutic DNA vaccine platform is primarily targeted at animal applications, with potential opportunities in human health as well. The T-Max platform addresses shortcomings of traditional viral vaccine technologies, aiming to create safe and efficacious vaccines for respiratory viral diseases with significant economic and social impacts.

The company's T-Max™ DNA vaccine platform sets itself apart through several key components, including a novel antigen selection process, cloning into proprietary plasmids, incorporation of immunomodulators, and CaptaVa. These elements work together to stimulate durable and potent T cell immune responses, with the potential to create cross-protective "universal" vaccines.

Founded in 2008, MBF Therapeutics operates within the biotechnology, health and wellness, and life sciences industries. The company recently received a $256.00K grant investment on 21 December 2021 from the National Science Foundation.

Taxonomy: immunotherapeutics, DNA vaccine, veterinary medicine, animal health, T-Max platform, respiratory viral diseases, porcine reproductive and respiratory syndrome, African swine fever, gene-based vaccines, checkpoint inhibitor therapies, canine oncology, infectious diseases, livestock vaccines, clinical-stage company, antigen selection